Welcome to our dedicated page for Inovio Pharmaceu news (Ticker: INO), a resource for investors and traders seeking the latest updates and insights on Inovio Pharmaceu stock.
Inovio Pharmaceuticals reports developments in DNA medicines for HPV-related diseases, cancer and infectious diseases. Its updates center on INO-3107, a DNA immunotherapy candidate for recurrent respiratory papillomatosis, including clinical data, scientific publications, FDA review milestones and presentations at medical and biotechnology conferences.
Company news also includes quarterly and annual financial results, business updates, research on DNA-encoded monoclonal antibodies and DNA-encoded protein technology, collaboration activity and capital-structure actions involving common stock, warrants and at-the-market financing programs.
INOVIO (NASDAQ: INO) announced a proposed underwritten public offering of common stock and accompanying Series A and Series B warrants (or pre-funded warrants) to purchase common stock.
The company said it will sell all securities offered, grant a 30-day underwriter option for up to 15% additional securities, and named Piper Sandler as sole manager. The offering is subject to market conditions and may not be completed.
INOVIO (NASDAQ: INO) will present at the World Federation of Hemophilia World Congress in Kuala Lumpur on April 22, 2026. The company will deliver a talk on DNA-Encoded Protein (DPROT) production of functional FVIII and a poster on non-viral DNA medicine FVIII expression in Hemophilia A mice.
Presentations are scheduled at 9:45 AM MYT (talk) and 10:45 AM MYT (poster). According to the company, abstracts will be posted on INOVIO's website after the presentations.
INOVIO (NASDAQ: INO) reported Q4 and full-year 2025 results and business updates, including a BLA acceptance for INO-3107 with a PDUFA target date of October 30, 2026. The FDA noted a potential issue on accelerated approval eligibility and agreed to meet. The company reported $58.5M cash and a projected runway into Q4 2026.
2025 financials: R&D $54.2M, G&A $32.7M, total operating expenses $86.9M, and a full-year net loss of $84.9M. INOVIO highlighted published clinical data and collaborations advancing its DNA medicine pipeline.
INOVIO (NASDAQ:INO) will present at two scientific conferences in March 2026. Eurogin HPV Conference (Vienna) on March 19 at 8:00 AM CET: presentation on DNA immunotherapy INO-3107 and long-term surgical intervention reduction in HPV-6 and HPV-11 RRP. World Vaccine Congress DC (Washington, DC) on March 30 at 11:50 AM ET: presentation on DNA-encoded monoclonal antibody technology for durable, tolerable in vivo mAb expression targeting COVID. Available abstracts will be posted on INOVIO's website after presentations.
INOVIO (NASDAQ:INO) will release fourth quarter and full year 2025 financial results after market close on March 12, 2026.
Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss results and provide a general business update; the webcast will be archived for 90 days.
INOVIO (NASDAQ: INO) and Akeso announced a clinical collaboration to evaluate INO-5412 plus Akeso's cadonilimab in glioblastoma as part of the Phase 2 INSIGhT adaptive platform trial.
Dosing is expected to begin in H2 2026. The program builds on prior positive Phase 2 immune responses with INO-5401 and leverages cadonilimab's China approvals and ongoing Phase 3/registration studies.
INOVIO (NASDAQ:INO) announced participation in multiple scientific and investor conferences between Feb 18 and Mar 10, 2026. Management will present posters and talks on INO-3107, SARS-CoV-2 DMAbs phase 1 data, and hold investor fireside chats and one-on-one meetings.
Webcasts and replay links are provided for investor events; abstracts will be posted on the company website after each presentation.
INOVIO (NASDAQ: INO) announced the U.S. FDA accepted its Biologics License Application (BLA) for INO-3107 to treat adults with recurrent respiratory papillomatosis (RRP).
FDA assigned a PDUFA goal date of October 30, 2026 and classified the review as Standard. The FDA indicated it is not currently planning an advisory committee meeting.
The BLA was filed under the accelerated approval pathway; FDA flagged a potential review issue, preliminarily finding inadequate information to justify accelerated approval. INOVIO plans to request a meeting with FDA and continues to believe INO-3107 meets accelerated approval criteria. The BLA includes Phase 1/2 data and long-term durability results published in Nature Communications and The Laryngoscope.
INOVIO (NASDAQ: INO) announced an equity inducement grant under its 2022 Inducement Plan for a newly hired employee. The Compensation Committee approved an option to purchase 24,000 shares with a Grant Date of November 28, 2025.
The option has an exercise price of $2.06 (INOVIO closing price on the Grant Date) and vests over three years with one-third vesting on each of the first, second and third anniversaries of the Grant Date, subject to continued employment and the terms of the stock option agreement. The award was granted in accordance with Nasdaq Listing Rule 5635(c)(4).
INOVIO (NASDAQ:INO) will participate in two investor conferences in New York in December 2025. Management will appear at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2 for an 8:30–8:55 AM ET fireside chat (live webcast and 90‑day replay available) and at the Oppenheimer Movers in Rare Disease Summit on Thursday, December 11 for a 12:05–12:25 PM ET panel featuring elevator pitches of near‑term catalysts. Members of INOVIO management will also hold one‑on‑one investor meetings during both events.
Webcast link for the Piper Sandler presentation: https://bit.ly/44af19l.